Abnormal tryptophan catabolism in diabetes mellitus and its complications: Opportunities and challenges - 13/09/23
, Hongwu Wang b, ⁎ 
Abstract |
In recent years, the incidence rate of diabetes mellitus (DM), including type 1 diabetes mellitus(T1DM), type 2 diabetes mellitus(T2DM), and gestational diabetes mellitus (GDM), has increased year by year and has become a major global health problem. DM can lead to serious complications of macrovascular and microvascular. Tryptophan (Trp) is an essential amino acid for the human body. Trp is metabolized in the body through the indole pathway, kynurenine (Kyn) pathway and serotonin (5-HT) pathway, and is regulated by intestinal microorganisms to varying degrees. These three metabolic pathways have extensive regulatory effects on the immune, endocrine, neural, and energy metabolism systems of the body, and are related to the physiological and pathological processes of various diseases. The key enzymes and metabolites in the Trp metabolic pathway are also deeply involved in the pathogenesis of DM, playing an important role in pancreatic function, insulin resistance (IR), intestinal barrier, and angiogenesis. In DM and its complications, there is a disruption of Trp metabolic balance. Several therapy approaches for DM and complications have been proven to modify tryptophan metabolism. The metabolism of Trp is becoming a new area of focus for DM prevention and care. This paper reviews the impact of the three metabolic pathways of Trp on the pathogenesis of DM and the alterations in Trp metabolism in these diseases, expecting to provide entry points for the treatment of DM and its complications.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abnormalities in Trp catabolism occur in DM and co-morbidities. A variety of therapeutic modalities for DM and its complications can modulate Trp catabolism.
Abnormalities in Trp catabolism occur in DM and co-morbidities. A variety of therapeutic modalities for DM and its complications can modulate Trp catabolism.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | Tryptophan catabolism is influenced by intestinal microorganisms. |
• | Recent advances in abnormal tryptophan catabolism in diabetes and complications. |
• | Some tryptophan catabolites can be used as risk markers for diabetes and complications. |
• | Role of tryptophan metabolites in diabetes. |
• | Tryptophan metabolism as a potential target for the treatment of diabetes and complications. |
Abbreviations : T1DM, T2DM, GDM, , Trp, , Kyn, , 5-HT, , IR, , DN, , DPN, , DKA, , DACI, , AD, , IPA, , IDO1/2, , Tna, , ArAT, , IP, , IAld, , IAA, , skate, , IA, , fldBC, , IBD, , Ahr, , PBMC, , IL-6, , IFN-λ, , TNF, , TAM, , GF, , KO, , SPF, Tryptophan 2, KATs, , KYNA, , KMO, , 3-HK, , 3-HAA, , XA, , 3-HAAO, , QUIN, , iNOS, , TpH2, , ECs, , 5-HTRs, , Trpa1, , HFD, , Gpr35, , IS, , DNP, , DR, , NPDR, , PDR, , Sus, , ARB, , BLC, , MD, , IF, , RYGB
Keywords : Diabetes, Diabetes complications, Tryptophan, Catabolism
Plan
Vol 166
Article 115395- octobre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
